Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) CEO Acquires 30,864 Shares of Stock

TriSalus Life Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Mary Szela bought 30,864 shares at an average price of $2.31, spending about $71,296 and increasing her direct stake by 2.87% to 1,105,854 shares.
  • TriSalus reported a quarterly loss of $0.15 per share, missing the $0.13 loss analysts expected; revenue of $12.88 million also fell short of the $14.02 million estimate. Shares traded at $2.17, near their one-year low of $2.16.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $9.20, though recent targets vary widely and some analysts have lowered theirs.
  • Five stocks we like better than TriSalus Life Sciences.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary Szela acquired 30,864 shares of the stock in a transaction on Tuesday, November 17th. The shares were acquired at an average cost of $2.31 per share, for a total transaction of $71,295.84. Following the completion of the transaction, the chief executive officer directly owned 1,105,854 shares in the company, valued at $2,554,522.74. The trade was a 2.87% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

TriSalus Life Sciences Stock Performance

TLSI stock traded down $0.28 during trading on Thursday, hitting $2.17. The company had a trading volume of 364,646 shares, compared to its average volume of 302,213. The firm has a 50-day moving average price of $3.90 and a 200-day moving average price of $4.26. The company has a quick ratio of 3.86, a current ratio of 4.22 and a debt-to-equity ratio of 47.60. The firm has a market cap of $133.62 million, a PE ratio of -4.43 and a beta of 0.50. TriSalus Life Sciences, Inc. has a 1-year low of $2.16 and a 1-year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The firm had revenue of $12.88 million during the quarter, compared to analyst estimates of $14.02 million. On average, analysts expect that TriSalus Life Sciences, Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on TLSI shares. Citigroup reaffirmed a "buy" rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Guggenheim set a $12.00 price objective on TriSalus Life Sciences in a report on Wednesday, September 23rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of TriSalus Life Sciences in a research note on Wednesday, November 4th. HC Wainwright reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Wednesday, November 11th. Finally, Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday, November 10th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, TriSalus Life Sciences has an average rating of "Moderate Buy" and an average target price of $9.20.

View Our Latest Report on TLSI

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in TLSI. Cura Wealth Advisors LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter valued at about $36,000. New York State Common Retirement Fund acquired a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $48,000. Russell Investments Group Ltd. acquired a new position in shares of TriSalus Life Sciences in the third quarter worth $68,000. Virtu Financial LLC purchased a new stake in TriSalus Life Sciences during the 3rd quarter worth about $79,000. Finally, Provenance Wealth Advisors LLC acquired a new position in TriSalus Life Sciences in the 3rd quarter valued at about $94,000. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

(Get Free Report)

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

Recommended Stories

Insider Buying and Selling by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TriSalus Life Sciences Right Now?

Before you consider TriSalus Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.

While TriSalus Life Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines